Conclusions
In ET patients on anagrelide with pericardial effusion, a drug-induced
etiology should be considered as an adverse reaction since it can
precipitate to cardiac tamponade; therefore, the decision to continue or
to stop anagrelide while managing the pericardial effusion should be
tailored to each patient individually through shared-decision making.
Acknowledgement: None
Conflict of Interest : None
Source of Funding : None